Home » AVEO Pharmaceuticals’ Monoclonal Antibody Exhibits Potent Inhibitory Activity
AVEO Pharmaceuticals’ Monoclonal Antibody Exhibits Potent Inhibitory Activity
AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, Wednesday announced
preclinical data which demonstrate that its Notch1-specific monoclonal antibody is a highly potent inhibitor of Notch1 function in both in vitro and in
vivo models.
MarketWatch
MarketWatch
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May